Foresite Capital Management Ii, LLC Jounce Therapeutics, Inc. Transaction History

Foresite Capital Management Ii, LLC

  • $29.2 Million
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 13, 2018
SELL
$12.52 - $17.82 $1.5 Million - $2.14 Million
-119,912 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
119,912
119,912 $1.68 Million

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Foresite Capital Management Ii, LLC Portfolio

Follow Foresite Capital Management Ii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management Ii, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email